Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: A meta-analysis

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 72, Issue 11-12, 2009, Pages 677-682

  Bai, Jianling ^a   Dai, Juncheng ^a   Yu, Hao ^a   Shen, Hongbing ^a   Chen, Feng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MDM2 PROTEIN, HUMAN; PROTEIN MDM2;

ARTICLE; CHEMICALLY INDUCED DISORDER; GENETIC PREDISPOSITION; GENETICS; HUMAN; LUNG TUMOR; META ANALYSIS; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; SMOKING;

EID: 67449103007     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390902840930     Document Type: Article

References (25)

1. Bagos, P. G., and Nikolopoulos, G. K. 2007. A method for meta-analysis of case-control genetic association studies using logistic regression. Stat. Appl. Genet. Mol. Biol. 6: Epub 2007.
2. Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., Onel, K., Yip, L., Hwang, S. J., Strong, L. C., Lozano, G., and Levine, A. J. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602.
3. Bond, G. L., Hu, W., and Levine, A. 2005. A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect. Cancer Res. 65:5481-5484.
4. DerSimonian, R., and Laird, N. 1986. Meta-analysis in clinical trials. Control Clin. Trials 7:177-188.
5. Egger, M., Davey Smith, G., Schneider, M., and Minder, C. 1997. Bias in metaanalysis detected by a simple, graphical test. Br. Med. J. 315:629-634.
6. Hu, Z., Jin, G., Wang, L., Chen, F., Wang, X., and Shen, H. 2007. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: Evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev. 16:2717-2723.
7. Hu, Z., Ma, H., Lu, D., Qian, J., Zhou, J., Chen, Y., Xu, L., Wang, X., Wei, Q., and Shen, H. 2006. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int. J. Cancer 118 :1275-1278.
8. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., and Thun, M. J. 2006. Cancer statistics, 2006. CA Cancer J. Clin. 56:106-130.
9. Jun, H. J., Park, S. H., Lee, W. K., Choi, J. E., Jang, J. S., Kim, E. J., Cha, S. I., Kim, D. S., Kam, S., Kim, C. H., Kang, Y. M., Jung, T. H., and Park, J. Y. 2007. Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol. Carcinogen. 46:100-105.
10. Lau, J., Ioannidis, J. P., and Schmid, C. H. 1997. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127:820-826.
11. Li, G., Zhai, X., Zhang, Z., Chamberlain, R. M., Spitz, M. R., and Wei, Q. 2006. MDM2 gene promoter polymorphisms and risk of lung cancer: A case-control analysis. Carcinogenesis 27:2028-2033.
12. Lind, H., Zienolddiny, S., Ekstrom, P. O., Skaug, V., and Haugen, A. 2006. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int. J. Cancer 119:718-721.
13. Liu, G., Wheatley-Price, P., Zhou, W., Park, S., Heist, R. S., Asomaning, K., Wain, J. C., Lynch, T. J., Su, L., and Christiani,D. C. 2008. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int. J. Cancer. 122 :915-918.
14. Murray, S. A., Yang, S., Demicco, E., Ying, H., Sherr, D. H., Hafer, L. J., Rogers, A. E., Sonenshein, G. E., and Xiao, Z. X. 2005. Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors. J. Cell. Biochem. 95:875-884.
15. Park, S. H., Choi, J. E., Kim, E. J., Jang, J. S., Han, H. S., Lee, W. K., Kang, Y. M., and Park, J. Y. 2006. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 54:19-24.
16. Petitti, D.B. 1994. Meta-analysis, decision analysis and cost-effectiveness analysis, pp. 101-103. New York: Oxford University Press.
17. Pine, S. R., Mechanic, L. E., Bowman, E. D., Welsh, J. A., Chanock, S. C., Shields, P. G., and Harris, C. C. 2006. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 15:1559-1561.
18. Pietenpol, J. A., and Stewart, Z. A. 2002. Cell cycle checkpoint signaling: Cell cycle arrest versus apoptosis. Toxicology 181-182:475-481.
19. Shields, P. G., and Harris, C. C. 2000. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J. Clin. Oncol. 18:2309-2315.
20. Thakkinstian, A., McElduff, P., D'Este, C., Duffy, D., and Attia, J. 2005. A method for meta-analysis of molecular association studies. Stat. Med. 24:1291-1306.
21. Vogelstein, B., Lane, D., and Levine, A. J. 2000. Surfing the p53 network. Nature 408:307-310.
22. Weber, H. O., Ludwig, R. L., Morrison, D., Kotlyarov, A., Gaestel, M., and Vousden, K. H. 2005. HDM2 phosphorylation by MAPKAP kinase 2. Oncogene 24:1965-1972.
23. Willis, A., Jung, E. J., Wakefield, T., and Chen, X. 2004. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23:2330-2338.
24. Wu, X., Zhao, H., Suk, R., and Christiani, D. C. 2004. Genetic susceptibility to tobacco-related cancer. Oncogene. 23:6500-6523.
25. Zhang, X., Miao, X., Guo, Y., Tan, W., Zhou, Y., Sun, T., Wang, Y., and Lin, D. 2006. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. 27:110-117.